139 related articles for article (PubMed ID: 29663854)
21. Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy.
Shimura T; Kakuda S; Ochiai Y; Kuwahara Y; Takai Y; Fukumoto M
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):540-8. PubMed ID: 21398050
[TBL] [Abstract][Full Text] [Related]
22. Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb.
Ma W; Yu J; Qi X; Liang L; Zhang Y; Ding Y; Lin X; Li G; Ding Y
Oncotarget; 2015 Jun; 6(18):15984-94. PubMed ID: 25961730
[TBL] [Abstract][Full Text] [Related]
23. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
24. [Association of epithermal growth factor receptor expression and its downstream gene mutation status with radiosensitivity of colorectal carcinoma cell lines in vitro].
Zuo ZG; Yu ZQ; Gao XH; Wang H; Zhang C; Liu QZ; Han YF; Chen LP; Zhang XQ; Fu CG
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):753-8. PubMed ID: 23980047
[TBL] [Abstract][Full Text] [Related]
25. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.
Minoo P; Moyer MP; Jass JR
J Pathol; 2007 Jun; 212(2):124-33. PubMed ID: 17427169
[TBL] [Abstract][Full Text] [Related]
26. Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis.
Lim MJ; Ahn JY; Han Y; Yu CH; Kim MH; Lee SL; Lim DS; Song JY
Int J Biochem Cell Biol; 2012 Aug; 44(8):1214-22. PubMed ID: 22564437
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
[TBL] [Abstract][Full Text] [Related]
28. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
30. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
Machida H; Matsumoto Y; Shirai M; Kubota N
Int J Radiat Biol; 2003 Dec; 79(12):973-80. PubMed ID: 14713575
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Endocrine; 2016 Oct; 54(1):129-138. PubMed ID: 27179656
[TBL] [Abstract][Full Text] [Related]
33. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
34. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Herr R; Köhler M; Andrlová H; Weinberg F; Möller Y; Halbach S; Lutz L; Mastroianni J; Klose M; Bittermann N; Kowar S; Zeiser R; Olayioye MA; Lassmann S; Busch H; Boerries M; Brummer T
Cancer Res; 2015 Jan; 75(1):216-29. PubMed ID: 25381152
[TBL] [Abstract][Full Text] [Related]
35. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
Ahn JH; Lee YW; Ahn SK; Lee M
Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of ATP-binding cassette subfamily C member 4 increases sensitivity to neoadjuvant radiotherapy for locally advanced rectal carcinoma.
Yu ZQ; Zhang C; Wang H; Lao XY; Chai R; Gao XH; Cao GW; Fu CG
Dis Colon Rectum; 2013 May; 56(5):600-8. PubMed ID: 23575399
[TBL] [Abstract][Full Text] [Related]
38. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
Walter L; Heinzerling L
Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
[TBL] [Abstract][Full Text] [Related]
39. Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer.
Hirschi B; Kolligs FT
Int J Cancer; 2013 Aug; 133(3):590-6. PubMed ID: 23354951
[TBL] [Abstract][Full Text] [Related]
40. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
Barras D; Missiaglia E; Wirapati P; Sieber OM; Jorissen RN; Love C; Molloy PL; Jones IT; McLaughlin S; Gibbs P; Guinney J; Simon IM; Roth AD; Bosman FT; Tejpar S; Delorenzi M
Clin Cancer Res; 2017 Jan; 23(1):104-115. PubMed ID: 27354468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
